Designing of Polymeric Nanoparticles for Enhanced Breast Cancer Therapy: Combining Paclitaxel, Boric Acid and Tannic Acid for Controlled Drug Delivery

Abstract

This study introduces an innovative approach to enhance breast cancer treatment by combining Boric Acid (BA) and Tannic Acid (TA) with Paclitaxel (PTX) within gelatin/sodium alginate (Gel/NaAlg) nanoparticles, resulting in a synergistic combination therapy. The methodology involved integrating PTX, TA, and BA into the polymeric framework using an emulsion cross‐linking method. The resulting nanoparticles underwent rigorous characterization, confirming their suitability as a controlled release platform. Techniques such as Scanning Electron Microscope (SEM), Differential Scanning Calorimetry (DSC), X‐ray Diffractometry (XRD), and Fourier Transform Infrared Spectroscopy (FTIR) were employed for thorough analysis. The synthesized nanoparticles demonstrated a size below 204 nm, and extensive analyses confirmed their structural integrity and composition. Notably, Gel/NaAlg/PTX/BA/TA nanoparticles exhibited superior drug release kinetics compared to other formulations, offering a promising strategy for controlled release of hydrophobic drugs like PTX. Entrapment efficiency ranged from 49.84 % to 63.38 %, and drug loading capacities spanned from 49.81 to 61.42 μg/mg. This study pioneers a novel approach in breast cancer therapy by incorporating BA and TA into PTX‐loaded Gel/NaAlg nanoparticlesThese findings emphasize the importance of continued exploration in innovative drug delivery systems for more effective cancer interventions.